Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 8/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 9/20 | 0.59 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.53 |
| ▸ | MMP7 | P09237 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669507 | 1.00 | MMP9 (0.60) | MMP9TDP1MMP2ADAMTS4CTSL | |
| Tpck SCHEMBL927265 | 0.89 | MMP9 (0.61) | MMP9TDP1MMP2ADAMTS4CTSL | |
| Tpck SCHEMBL441444 | 0.89 | MMP9 (0.61) | MMP9TDP1MMP2ADAMTS4CTSL | |
| SCHEMBL11146335 | 0.88 | GAA (0.51) | MMP9TDP1MMP2ADAMTS4CTSL | |
| SCHEMBL4504106 | 0.88 | MMP9 (0.47) | MMP9TDP1MMP2ADAMTS4CTSL | |
| SCHEMBL16401520 | 0.88 | MMP9 (0.47) | MMP9TDP1MMP2ADAMTS4CTSL | |
| SCHEMBL1523717 | 0.86 | MMP9 (0.69) | MMP9TDP1MMP2ADAMTS4CTSL | |
| SCHEMBL433895 | 0.86 | MMP9 (0.69) | MMP9TDP1MMP2ADAMTS4CTSL | |
| SCHEMBL628639 | 0.86 | MMP9 (0.64) | MMP9TDP1MMP2ADAMTS4CTSL | |
| Chloromethane SCHEMBL7649372 | 0.86 | MMP2 (0.75) | MMP9TDP1MMP2ADAMTS4CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5731198-A | COMPRISING AN ENZYME INHIBITOR SUPPORTED ON A POROUS MEMBER | EMERALD BIOMEDICAL SCIENCES, INC. (US) | 1998-03-24 | — | — | US | claimed |
| US-5385825-A | An enzyme inhibitor consisting of blood, ethylenediamine tetraacetic acid and at least one compound from N-tosyl-lysyl chloromethylketone and N-tosyl-phenylalanyl chloromethylketone ; radioimmunoassay detecting a protein or hormone analyte | EMERALD BIOMEDICAL SCIENCES, INC. (US) | 1995-01-31 | — | — | US | claimed |
| JP-5097708-A | — | — | None | — | — | JP | disclosed |
| US-12590288-B2 | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response | THE BROAD INSTITUTE, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12227578-B2 | Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action | THE BROAD INSTITUTE, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| CN-114072417-B | Recombinant nonstructural protein 1, recombinant influenza virus and immune composition containing same and application of recombinant nonstructural protein 1 and immune composition in preparation of influenza virus vaccine composition | 凌斌 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024103215-A1 | PHARMACEUTICAL COMBINATION FOR TREATING FATTY LIVER DISEASE AND USE THEREOF | 泽生生技股份有限公司 | 2024-05-23 | — | — | WO | disclosed |
| US-20240018218-A1 | ANTIVIRAL COMPOSITION AGAINST INFLUENZA A VIRUS | NOVELGEN CO., LTD. (KR) | 2024-01-18 | — | — | US | disclosed |
| EP-4212548-A1 | ANTIVIRAL COMPOSITION AGAINST INFLUENZA A VIRUS | Novelgen Co., Ltd. (KR) | 2023-07-19 | — | — | EP | disclosed |
| CN-115386596-A | Trans-replicating RNA | 生物技术公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-109328233-B | Trans-replicating RNA | 生物技术公司 | 2022-10-11 | — | — | CN | disclosed |
| US-5543312-A | GENE EXPRESSION, CLONING A DNA SEQUENCE | UNIVERSITY OF GUELPH (CA) | 1996-08-06 | — | — | US | disclosed |
| US-5457066-A | Treating with trypsin and carboxypeptidase b in aqueous medium containing nickel ions in specified concentrations and weight ratios | ELI LILLY AND COMPANY (US) | 1995-10-10 | — | — | US | disclosed |
| US-5385825-A | An enzyme inhibitor consisting of blood, ethylenediamine tetraacetic acid and at least one compound from N-tosyl-lysyl chloromethylketone and N-tosyl-phenylalanyl chloromethylketone ; radioimmunoassay detecting a protein or hormone analyte | EMERALD BIOMEDICAL SCIENCES, INC. (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0264250-B1 | Process for transforming a human insulin precursor to human insulin | LILLY CO ELI (US) | 1994-12-21 | — | — | EP | disclosed |
| JP-H0597708-A | TREATING AGENT FOR IMPROVING PERIODONTITIS | LION CORP | 1993-04-20 | — | — | JP | disclosed |
| EP-0310030-A1 | Cloning of DNA encoding transcription factor S-11 and utilization of the DNA | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1989-04-05 | — | — | EP | disclosed |
| EP-0264250-A2 | Process for transforming a human insulin precursor to human insulin | ELI LILLY AND COMPANY (US) | 1988-04-20 | — | — | EP | disclosed |
| US-4503035-A | HUMAN LEUKOCYTE INTERFERON | HOFFMANN-LA ROCHE INC. (US) | 1985-03-05 | — | — | US | disclosed |
| US-4289690-A | HIGH PERFORMANCE LIQUID CHROMATOGRAPHY TO PURIFY INTERFERON | HOFFMANN-LA ROCHE INC. (US) | 1981-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590288-B2 | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response | GPR3, GALR3, NR4A3 | MMP9 4588/4885TDP1 4756/4885MMP2 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.